Arcturus Therapeutics Holdings Inc

ARCT.US
Healthcare · Biotechnology
5.75
-0.01 (-0.17%)
USD · NASDAQ

Company Information

Company Name
Arcturus Therapeutics Holdings Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US03969T1097
CIK: 0001768224
CUSIP: 03969T109
Currency: USD
Full Time Employees: 106
Phone: 858 900 2660
Fiscal Year End: December
IPO Date: Apr 16, 2020
Description:

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Address:

10285 Science Center Drive, San Diego, CA, United States, 92121

People

Directors & Officers

Name Title Year Born
Mr. Joseph E. Payne M.Sc. Founder, President, CEO & Director 1972
Dr. Padmanabh Chivukula Ph.D. Founder, Chief Scientific Officer, COO & Secretary 1979
Mr. Joseph Roberts Principal Accounting Officer & Controller 1983
Mr. Lance Kurata Chief Legal Officer NA
Mr. Dennis M. Mulroy Chief Financial Officer 1955
Ms. Neda Safarzadeh Vice President and Head of IR/PR & Marketing NA
Ms. Natasha O. Bowman Chief Human Resources Officer NA
Mr. Kevin T. Skol Chief Business Officer NA
Dr. Igor Smolenov M.D., Ph.D. Chief Development Officer NA
Dr. Ye Zhang Chief Regulatory & Quality Assurance Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 15, 2024 Pad Chivukula N/A Sale 12.00K $20.76 $249.12K
Jun 05, 2024 Pad Chivukula N/A Sale 114.00 $45.00 $5.13K
Jun 03, 2024 Pad Chivukula N/A Sale 26.00K $40.01 $1.04M
Mar 25, 2024 Pad Chivukula N/A Sale 17.44K $35.02 $610.57K
Mar 19, 2024 Pad Chivukula N/A Sale 8.57K $35.01 $299.86K
Nov 01, 2023 Pad Chivukula N/A Sale 5.00K $18.72 $93.60K
Oct 02, 2023 Pad Chivukula N/A Sale 5.00K $25.61 $128.05K
Sep 01, 2023 Pad Chivukula N/A Sale 5.00K $31.45 $157.25K
Jul 14, 2023 Keith C Kummerfeld N/A Sale 6.97K $35.00 $243.88K
Jul 14, 2023 Pad Chivukula N/A Sale 25.00K $35.01 $875.25K
Jul 03, 2023 Pad Chivukula N/A Sale 5.00K $28.75 $143.75K
May 10, 2023 Pad Chivukula N/A Sale 17.08K $30.00 $512.25K
May 01, 2023 Pad Chivukula N/A Sale 5.00K $25.93 $129.65K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Federated Hermes Inc 3.30M Mar 31, 2026 11.62% $0.04 0.00%
ARK Investment Management LLC 2.77M Mar 31, 2026 9.74% $0.17 6.07%
BlackRock Inc 2.61M Mar 31, 2026 9.19% $0.00 -0.24%
Amova Asset Management Americas, Inc 2.29M Mar 31, 2026 8.05% $0.25 12.95%
Sumitomo Mitsui Trust Group Inc 2.29M Mar 31, 2026 8.05% $0.01 12.95%
Vanguard Group Inc 2.09M Dec 31, 2025 7.35% $0.00 10.82%
Vanguard Capital Management, LLC 1.11M Mar 31, 2026 3.89% $0.00 0.00%
Two Sigma Investments LLC 1.08M Mar 31, 2026 3.81% $0.01 97.88%
Vanguard Portfolio Management, LLC 977.92K Mar 31, 2026 3.44% $0.00 0.00%
Geode Capital Management, LLC 660.93K Mar 31, 2026 2.33% $0.00 6.92%
State Street Corp 543.86K Mar 31, 2026 1.91% $0.00 -3.62%
Two Sigma Advisers, LLC 511.04K Dec 31, 2025 1.80% $0.01 1,227.38%
Millennium Management LLC 478.56K Mar 31, 2026 1.68% $0.00 57.02%
UBS Group AG 458.28K Mar 31, 2026 1.61% $0.00 101.09%
Empire Life Investments Inc 383.49K Mar 31, 2026 1.35% $0.18 -7.01%
Hennion & Walsh Asset Management Inc 346.21K Jun 30, 2026 1.22% $0.07 23.79%
Dimensional Fund Advisors, Inc. 288.36K Mar 31, 2026 1.01% $0.00 -41.20%
Acadian Asset Management LLC 280.50K Mar 31, 2026 0.99% $0.00 531.40%
Heartland Advisors Inc 256.00K Mar 31, 2026 0.90% $0.10 0.00%
D. E. Shaw & Co LP 252.03K Mar 31, 2026 0.89% $0.00 157.64%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 ARK Genomic Revolution ETF 2.79M 9.82% ▲ 3.01% Jun 30, 2026
2 ARK Genomic Revolution 2.75M 9.69% ▲ 4.61% Jun 30, 2026
3 Federated Hermes Kaufmann Growth 2.07M 7.29% ▲ 0.00% Mar 31, 2026
4 Federated Hermes Kaufmann R 2.07M 7.29% ▲ 0.00% Mar 31, 2026
5 Amova ARK Pstv Chg Innovt P JPY Acc 1.87M 6.57% ▼ 4.22% May 31, 2026
6 Federated Hermes Kaufmann Small Cap Grow 1.19M 4.18% ▲ 0.00% Mar 31, 2026
7 Federated Hermes Kaufmann Small Cap A 1.19M 4.18% ▲ 0.00% Mar 31, 2026
8 Vanguard Total Stock Mkt Idx Inv 797.15K 2.80% ▲ 0.00% Jun 30, 2026
9 iShares Russell 2000 ETF 716.65K 2.52% ▲ 0.60% Jun 30, 2026
10 Vanguard Institutional Extnd Mkt Idx Tr 293.10K 1.03% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $163.72M
EBITDA: $-85.48M
Book Value: $6.73
Earnings/Share: $-2.95
Profit Margin: -143.80%
Operating Margin: -1,403.74%
ROA (TTM): -19.14%
ROE (TTM): -37.01%
Revenue (TTM): $54.71M
Revenue/Share (TTM): $1.97
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -93.00%

Valuation Metrics

Enterprise Value: $-30.21M
Trailing P/E: 0.00
Forward P/E: 2.48

Shares Statistics

Shares Outstanding: 28.42M
Shares Float: 26.15M
% Insiders: 798.60%
% Institutions: 8,052.00%
Short % Float: 30.65%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$67.22M
Cost of Goods Sold
adjust
$-3.03M
Gross Profit
subtotal
$64.20M
SG&A
adjust
$-46.08M
R&D
adjust
$-112.21M
Operating Income
subtotal
$-74.96M
Other / Non-Operating Items
adjust
$9.17M
Net Income
subtotal
$-65.78M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ARCT.US!